[go: up one dir, main page]

AU2002255880A1 - Aberrantly expressed proteins in laser capture microdissected tumors - Google Patents

Aberrantly expressed proteins in laser capture microdissected tumors

Info

Publication number
AU2002255880A1
AU2002255880A1 AU2002255880A AU2002255880A AU2002255880A1 AU 2002255880 A1 AU2002255880 A1 AU 2002255880A1 AU 2002255880 A AU2002255880 A AU 2002255880A AU 2002255880 A AU2002255880 A AU 2002255880A AU 2002255880 A1 AU2002255880 A1 AU 2002255880A1
Authority
AU
Australia
Prior art keywords
expressed proteins
laser capture
aberrantly expressed
capture microdissected
tumors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002255880A
Inventor
Michael R. Emmert-Buck
Lance A. Liotta
Emanuel Frank Petricoin Iii
Yingming Zhao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Icahn School of Medicine at Mount Sinai
US Department of Health and Human Services
Original Assignee
Mount Sinai School of Medicine
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mount Sinai School of Medicine, US Department of Health and Human Services filed Critical Mount Sinai School of Medicine
Publication of AU2002255880A1 publication Critical patent/AU2002255880A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57449—Specifically defined cancers of ovaries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
AU2002255880A 2001-03-22 2002-03-22 Aberrantly expressed proteins in laser capture microdissected tumors Abandoned AU2002255880A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27804801P 2001-03-22 2001-03-22
US60/278,048 2001-03-22
PCT/US2002/008847 WO2002077176A2 (en) 2001-03-22 2002-03-22 Aberrantly expressed proteins in laser capture microdissected tumors

Publications (1)

Publication Number Publication Date
AU2002255880A1 true AU2002255880A1 (en) 2002-10-08

Family

ID=23063475

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002255880A Abandoned AU2002255880A1 (en) 2001-03-22 2002-03-22 Aberrantly expressed proteins in laser capture microdissected tumors

Country Status (2)

Country Link
AU (1) AU2002255880A1 (en)
WO (1) WO2002077176A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT412026B (en) * 2002-02-07 2004-08-26 Illmensee Karl Dr METHOD FOR DIAGNOSING A CYSTIC OVARIAL CARCINOMA
JP4282086B2 (en) 2003-06-06 2009-06-17 エフ．ホフマン−ラ ロシュ アーゲー Use of protein cellular retinoic acid binding protein II (CRABPII) as a marker for breast cancer
WO2005036180A1 (en) * 2003-10-08 2005-04-21 The Government Of The United States Of America As Represented By The Secretary Of Department Of Health And Human Services Analysis methods using biomarkers concentrated with biomarkers attractant molecules
WO2005124357A1 (en) * 2004-06-18 2005-12-29 Roche Diagnostics Gmbh Use of protein elongation factor-1-alpha-1 as a marker for breast cancer
EP1759020A4 (en) * 2004-06-21 2008-04-16 Exelixis Inc Acacs as modifiers of the igf pathway and methods of use
US20100173788A1 (en) * 2005-06-21 2010-07-08 Vermillion, Inc. Biomarkers for breast cancer
US20070077583A1 (en) * 2005-09-21 2007-04-05 Aurelium Biopharma, Inc. Alpha enolase-directed diagnostics and therapeutics for cancer and chemotherapeutic drug resistance
WO2007060240A2 (en) * 2005-11-25 2007-05-31 Institut National De La Sante Et De La Recherche Medicale (Inserm) Method for demonstrating presence or absence of markers (eef1a1 or mark3 )associated with the presence and/or the chemosensitivity of tumors
FR2894031A1 (en) * 2005-11-25 2007-06-01 Genome Express S A Sa METHOD FOR THE PRESERVATION OF THE PRESENCE OR ABSENCE OF MARKERS ASSOCIATED WITH THE CHEMOSENSITIVITY OF TUMORS
EP2013618B1 (en) * 2006-04-28 2013-04-10 Singapore Health Services Pte Ltd Investigation of mucosa dryness conditions
IL177609A (en) 2006-08-21 2015-11-30 Yaron Ilan Use of gabaculine or its analog in the manufacture of a medicament for treating hepatocellular carcinoma
CN100479863C (en) * 2006-09-06 2009-04-22 中国医学科学院北京协和医院 Correlation of cofilin 1 and resistance to anticancer taxane chemotherapy medicine
WO2009009890A1 (en) * 2007-07-16 2009-01-22 University Health Network Ovarian cancer biomarkers
KR101431062B1 (en) * 2012-03-08 2014-08-21 (주)바이오메디앙 Multiple biomarker set for breast cancer diagnosis, method of detecting the same, and diagnosis kit for breast cancer using antibody against the same
CN116688096A (en) 2016-02-04 2023-09-05 免疫系统密钥有限公司 Endoplasmic reticulum stress as a predictive tool in cancer therapy and combination therapy for cancer treatment
CN110031625A (en) * 2019-03-31 2019-07-19 苏州市立医院 Detection reagent and its application comprising 5 antibody of phosphoglucomutase

Also Published As

Publication number Publication date
WO2002077176A3 (en) 2004-04-01
WO2002077176A2 (en) 2002-10-03

Similar Documents

Publication Publication Date Title
AU2001256129A1 (en) Laser microdissection device
AU2001241848A1 (en) Methods for manipulating data in multiple dimensions
AU2002255880A1 (en) Aberrantly expressed proteins in laser capture microdissected tumors
AU2002305148A1 (en) Imaging systems for in vivo protocols
AUPR509801A0 (en) Boundary finding in dermatological examination
AU2002304814A1 (en) Protein-protein interactions in adipocytes
AUPR564501A0 (en) Apparatus for use in pumps
AU2002301358A1 (en) Improvements in Transmissometers
AU2002341828A1 (en) Enhanced proteins and methods for their use
AU2001271286A1 (en) Apparatus for microchip laser geo-sensors
AU2001283207A1 (en) Novel motor proteins and methods for their use
AU2001266961A1 (en) Novel motor proteins and methods for their use
AU2002323051A1 (en) Metal-binding proteins
AU2001297707A1 (en) Motor proteins and methods for their use
AU2001264726A1 (en) Novel motor proteins and methods for their use
AU2002329977A1 (en) In vitro protein translation microarray device
AU2001268099A1 (en) Novel motor proteins and methods for their use
AU2002328115A1 (en) Phosphatidylinositol 5-phosphate-binding proteins
AU2002306879A1 (en) Cytoskeleton-associated proteins
AU2002243119A1 (en) Device for moving an aircraft in space
AUPR473801A0 (en) Improvements in components
AUPR830601A0 (en) Improvements in means for joining
AU2001268637A1 (en) Novel motor proteins and methods for their use
AU2001269355A1 (en) Greeting card
AUPR771701A0 (en) Casino card game - lucky streak

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase